Latest News and Press Releases

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn)...

Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc...

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...

Sunstone Therapies Announces Expansion of Innovative Dyad Study Expansion of Phase 2 pilot trial to assess MDMA-assisted therapy for adjustment disorder in dyads of patients with cancer and a...

Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy ...

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 June 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...

Phase 2 data shows sustained response in 80% of patients and 50% of patients in full remission of depressive symptoms Use of group setting and 1:1 patient to therapist ratio has...

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...

PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable...